Comparisons can be odious

T. BETTS
When I first started working in the field of epilepsy, over 25 years ago, therapeutic options were much more limited than they are today. Surgery had not yet reached an established place in the management of intractable epilepsy and the pharmaceutical industry seemed little interested in producing better drugs for treating the condition with fewer side-effects. By comparison, with the pressure today to use new drugs, the manufacturers who had just introduced carbamazepine and sodium valproate for the treatment of epilepsy seemed almost apologetic about their products. Extensive double blind clinical trials and evidence based medicine were very far away. The almost daily visits of keen drug representatives extolling the virtues of his or her anticonvulsant which we experience nowadays did not occur.
We were left much more to our own endeavours and gradually learned to use the new anticonvulsants, discovering for ourselves both their virtues and their drawbacks, developing a clinical practice with them based largely on our own experience and the experience of colleagues that we trusted. My mentor, for instance, was Peter Jeavons who taught me to use valproate in his own unique way (using weight related doses, monitoring EEG responses as a guide to sufficient dosage and totally .ignoring blood levels). Likewise I learned the value from him of low, slow dose escalations of carbamazepine (so low and slow in fact that I have never personally caused a carbamazepine rash).
I was learning my epilepsy skills in the seventies. Part of my research at that time was to study the effect of various prescribed drugs on cerebral function--particularly their effects on mood and psychomotor performance (especially as related to their possible detrimental influence on driving skills). As a result, for some time, I rubbed shoulders with physicians in the hypertension field at a time when there was a sudden surge in interest in the management of hypertension with somewhat less poisonous compounds than we had used previously; particularly the beta blocking drugs which were competing actively with each other to be the best antihypertensive with fewest side-effects.
Debate raged as to whether lipid solubility was better than water solubility. Was some ISA activity necessary in your beta blocker? Was it better to have a beta blocker that penetrated the central nervous system or one that did not? Was Beta 2 activity a good thing or not? Debate, claims and counterclaims, were endless. As what seemed like dozens of compounds, all with slightly different properties, hit the market, polite young men and women in suits tried to persuade us of the outstanding virtues of their own particular product. At cardiological meetings endless Satellites were held in which men in slightly more expensive suits (the opinion leaders so beloved of the pharmaceutical industry) held forth about the virtues of different types of beta blocker. A plethora of pens, notepads and other little gifts suddenly appeared on doctors' desks all discretely labelled with the trade name of a particular beta blocker.
Perhaps the competition of these heady days was a waste of money and resources but it did lead in its own insidious way to a great deal of basic research into the mechanisms of hypertension itself, which eventually led to better drugs with fewer side-effects and better understanding of the whole process of hypertension and some insight into the quality of life of people taking drugs for very long periods of time to control blood pressure. For the first time physicians did not treat hypertension as though they were just treating a column of mercury but began to think about the person with the raised blood pressure.
Epileptologists are now, fairly suddenly, being exposed to a similar kind of pressure. In the last five years Several new compounds have emerged, (one or two to disappear almost as quickly as they had arrived) but some clearly becoming established and fighting for a place in the anticonvulsant market. Polite young women and men (still in suits) are appearing in our consulting rooms extolling the virtues of a particular new anticonvulsant: competing claim succeeds competing claim.
But a new element has entered into this world. Back in the seventies it never crossed my mind to wonder how much the drugs we were using actually cost. I was actually much freer to make my own decisions about which drug was going to be of particular benefit to a particular patient. Now we all have to think of health costs. The new drugs are much more expensive than the old. Again young men and women (still in suits--the new managers) are now monitoring the cost of epilepsy health care and beginning to question whether we should be using the new compounds at all since they are perhaps at least ten times as expensive as the old. Some of our colleagues make a virtue of cost consciousness by using it to justify their therapeutic conservatism. Yet other young men and women (still in suits--since they are mostly psychologists) are now teaching us to ask different questions about our medication: not just in terms of how effective it is but whether it improves patients' quality of life.
Even neurologists, who are perhaps the most conservative of us, are now talking earnestly about quality of life and its measurement. So converted are they to the notion of improving 'Quality of Life' that they are beginning to talk and write as though they invented it, thus causing wry amusement amongst psychiatrists who have been writing on the topic for at least the last 50 years and have been paying more than lip service to it.
One of the problems for the manufacturers of new antiepileptic compounds is that their development is extremely slow. Manufacturers must look back in envy to the days when phenytoin was synthesized, tested and put onto the market within about three years. Nowadays it may be 10-12 years before a drug is licenced to go on the market and vast sums have been spent on rigorous safety and efficacy testing before it does. Another problem is that the efficacy of the drug is tested on a population of patients with chronic partial seizures who are resistant to conventional medication and who are not suitable (or are waiting) for surgery. A manufacturer who is just star.ting to test his new compound today is therefore faced with carrying out these tests on a group of patients who may already have failed with phenytoin, carbamazepine, sodium valproate, vigabatrin, lamotrigine, gabapentin, topiramate and tiagabine and probably therefore are resistant to anything they are ever likely to be offered.
It seems to me that an expanding army of new anticonvulsants is chasing a diminishing guerilla band of resistant patients: their numbers lessening with every new successful compound. In clinics like mine how many patients can be found who regularly have at least four partial seizures a month and are prepared to undergo extensive baseline monitoring? Most such patients nowadays are only to be found in the ranks of the learning impaired who are excluded from most trials. Some manufacturers are starting to contemplate doing initial trials in the economically disadvantaged parts of the world (with all the logistical and ethical problems such an approach brings with it) as the supply of suitable patients in the western world dries up.
We have to fall back on statistical manipulation of data to show that a significant number of trial patients had a 50% reduction in seizure .frequency compared with placebo thus 'proving' that the drug is probably effective (whereas clinicians--and patients--are more concerned with how many patients in the trial became seizure free). Doses used are often mere guesswork: because the patients are so resistant and so enzymeinduced, the chosen dose may have no relationship at all to the effective dose in a patient population that is not resistant to anticonvulsants. Very few of the resistant group of patients are likely to become seizure free on the drug and if they do their freedom from seizures may be short-lived.
Showing a drug to be effective in properly conducted double blind placebo controlled trials may tell us very little about how effective the drug is going to be in the population of patients we normally treat. Eventually of course the new drug comes into direct competition with an older standard drug (usually carbamazepine) on a head to head basis in a monotherapy trial in patients with newly established seizures.
Such monotherapy trials do not usually have a placebo condition in them although I have more than a sneaking suspicion that placebos might do very well in such trials (particularly because we know that at least 30% of people who start having epilepsy will lose it for themselves without needing any medication). It is easy to unintentionally manipulate the results of monotherapy trials with new compounds particularly if one is measuring quality of life and side-effect profiles as well. One such recent trial I was asked to take part in involved a starting dose of the comparator carbamazepine that was so high that I would not have been surprised if every patient dropped out of the carbamazepine arm of the trial almost immediately due to side-effects. The dose of the new drug was much lower than the one used in the add-on double blind trials that had preceded this particular trial. Was this to minimize side-effects? I declined the invitation to take part in this trial and I am not certain it went ahead.
Therefore it is often not until the drug has actually got onto the market that one really begins to learn in what group of patients it is effective, what its side-effects are and what dose is actually needed to produce a reasonable effect. This is why results of open trials (although derided by some) can be useful. Providing careful records are kept and careful audit made of the clinician's experience the results of such trials can be helpful as a guide to other clinicians who are starting to use the drug in question.
When the drug has been on the market for a few years it can be helpful to present careful audit of its use in particular clinics which again may give some indication as to wheter it really fits into the therapeutic profile.
We are certainly prepared in Seizure to publish careful audits of the clinical use of new compounds providing that relevant data has been collected properly and that the audit is presented (as double blind trials are presented) on an 'intention to treat' basis. We recently rejected an audit paper of one of the new compounds (which gave it a very favourable impression). The audit was trying to establish whether tolerance developed to the initial beneficial effects of this particular compound. Unfortunately this particular audit did not commence until the patients had been taking the new drug for at least six months and therefore ignored those patients who started it but who subsequently stopped taking it fairly rapidly (for various reasons), thus skewing the results of the audit to favour the drug.
What one has yet to see in the scientific literature are proper head to head comparisons between the new compounds themselves. If tested head to head in a comparable population would vigabatrin really be more powerful than lamotrigine but have more side-effects? Would gabapentin be less powerful than lamotrigine but have fewer side-effects? We need to establish the scientific answer to these questions particularly because as competition hots up between the new compounds (and as the young men and women in their suits become more vociferous in persuading us that their particular compound is better) we are reaching a position where invidious and unfair comparisons are being drawn between the new compounds based on the results of earlier double blind trials in resistant patients. Recently the sales pitch of one particular new compound suggested that it was superior to other new compounds because meta analysis of its trials in resistant patients showed that significantly more patients reached the 'magic' figure of 50% seizure reduction in its trials than in comparable trials of its competitors: so therefore this drug should be the logical first line add-on drug.
I think we should not be taken in by this--like is not being compared with like. The relative proportion of patients in the various trials who had partial seizures only or who had partial seizures with secondary generalization was different: the higher the proportion of the latter in a clinical trial the more likely it is that there will be a better result. How many patients in lamotrigine trials were already vigabatrin resistant? How many in gabapentin trials were already vigabatrin and lamotrigine resistant? Were patients in topiramate trials naive to exposure to the other new compounds? These factors will very much affect the outcome of a trial. Only head to head trials should be used for direct comparisons between the new drugs.
Even if direct head to head comparisons are made, efficacy in seizure control is not the whole issue: quality of life and side-effect profile are equally important and must also be addressed. Some clinicians engaged to speak in Satellite Symposia on the relative efficacy of the new anticonvulsants are beginning to draw up league tables of efficacy and are beginning to suggest that certain of the new compounds should be the first add on compound in patients whose epilepsy is resistant to conventional medication. Most such league tables seem to concentrate on anticonvulsant efficacy and ignore side-effects (with the exception of Martin Brodie's Star System). Most patients, however, offered the choice between two drugs, one of which had 10% better efficiency but more side-effects and another which was potentially less efficient but had fewer significant side-effects, would probably choose the latter (rather than be told what to take by an imperious specialist who has never had to make the choice personally). Should We also have league tables for men and women separately? A particular drug might be the logical first choice add-on drug but if it is teratogenic it surely cannot be so for women of child bearing potential?
We publish in this issue of Seizure a different type of comparison of new compounds based on economic rather than clinical criteria: cost rather than just efficacy. This paper is likely to be controversial and not everyone will agree with it, but our referees feel that it is worth publishing if only to invite comment and discussion. Because this is an economic rather than a clinical paper it makes certain assumptions about the three new compounds it is evaluating particularly in terms of their clinical efficacy. It also makes assumptions about the clinical doses of these compounds and the consequences of management, and the seriousness of, side-effects which not everybody will agree with. I felt, after some consideration, that this paper was worth publishing for your consideration and to promote discussion about whether cost should be a consideration that we should take into account when considering the efficiency of new antiepileptic compounds. In this era of intense competition between manufacturers of antiepileptic drugs (which we have never experienced before) we need to be able to make our own informed judgments.
